Claire L. Fellman - DVM, PhD, DACVIM, DACVCP

Claire L. Fellman
Internal Medicine (Small Animal) / Clinical Pharmacology

Dr. Claire Fellman is a small animal internist with interests in pharmacology and immunology.  Dr. Fellman grew up as a child of the Air Force moving around the world with her family, dog, and cat, before settling in Mississippi in 2000.  She received her bachelor’s degree in biological engineering at Mississippi State University before starting veterinary school, and then became involved in a research project investigating the effects of cyclosporine on the immune system in dogs as part of a summer research project.  This experience led Dr. Fellman to begin a PhD, and complete her clinical training with a Small Animal Internal Medicine residency and Clinical Pharmacology residency, all at Mississippi State University.  Dr. Fellman finished her training and began a faculty position at Tufts University in 2016. 

Dr. Fellman enjoys treating immune-mediated diseases and working to identify more effective treatment strategies for animals.  She is also passionate about cats and has 4 at home in Worcester, along with her dog, and archaeologist fiancé, Joseph. 

Education

  • PhD – Veterinary Medical Science, Mississippi State University, 2016
  • DVM – Mississippi State University, 2011
  • BS – Biological Engineering, Mississippi State University, 2006

Board Certification

  • American College of Veterinary Internal Medicine (ACVIM), Small Animal Internal Medicine
  • American College of Veterinary Clinical Pharmacology (ACVCP)
  • Fellman C, Archer T, Stokes J, Wills R, Lunsford K, Mackin A. 2016. Effects of oral cyclosporine on canine T cell expression of IL-2 and IFN-gamma across a 12-h dosing interval. Journal Veterinary Pharmacology and Therapeutics. 39(3): pp. 237-44.
  • Archer T, Fellman C. 2015. Words of Caution: Cyclosporine. Plumb’s Therapeutics Brief. Jan, pp. 8-11.
  • Haraschak J, Langston V, Wang R, Riggs C, Fellman C, Ross M, Bulla C, Lunsford K, Mackin A, Archer T. 2014. Pharmacokinetic evaluation of oral dantrolene in the dog. Journal of Veterinary Pharmacology and Therapeutics.37 (3): pp. 286-294.
  • Archer T, Boothe D, Langston V, Fellman C, Lunsford K, Mackin A. 2014. Oral cyclosporine treatment in dogs: A review of the literature. Journal of Veterinary Internal Medicine. 28 (1): pp. 1-20.
  • Riggs C, Archer T, Fellman C, Figueiredo AS, Follows J, Stokes J, Mackin A, Bulla C. 2013. Analytical validation of a quantitative reverse transcriptase polymerase chain reaction assay for evaluation of T-cell targeted immunosuppressive therapy in the dog. Veterinary Immunology and Immunopathology. 156: pp. 229-234.
  • Archer T, Fellman C, Stokes J, Pinchuk L, Lunsford K, Pruett S, Langston V, Mackin A. 2011. Pharmacodynamic monitoring of canine T-cell responses to oral cyclosporine. Journal of Veterinary Internal Medicine. 25 (6): pp. 1391-1397.
  • Fellman C, Stokes J, Archer T, Pinchuk L, Lunsford K, Mackin A. 2011. Cyclosporine A affects the in vitro expression of T cell activation-related molecules and cytokines in dogs. Veterinary Immunology and Immunopathology. 140: pp. 175-180.

General Research Interests

  • Immunosuppressive drugs, especially cyclosporine
  • Pharmacodynamics
  • T cell immunology
  • Antibiotic resistance

Research and Clinical Interests

  • Immune-mediated disease
  • Clinical immunology
  • Hematology
  • Pharmacology
  • Feline medicine